Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare
暂无分享,去创建一个
D. Kalra | A. Hackshaw | B. Borisch | K. Facey | A. Chiti | D. Horgan | C. Chomienne | B. Tumienė | A. Cole | M. Caulfield | Martina von Meyenn | Ivana Cattaneo | Minna Hendolin | Nadia Georges
[1] R. Chilton,et al. Real-world evidence and product development: Opportunities, challenges and risk mitigation , 2021, Wiener klinische Wochenschrift.
[2] A. Gajra,et al. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[3] Elizabeth M. Hechenbleikner,et al. Data explosion during COVID-19: A call for collaboration with the tech industry & data scrutiny , 2020, EClinicalMedicine.
[4] M. P. Douglas,et al. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] Dane Dickson,et al. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine , 2020, Cell.
[6] S. Sleijfer,et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs , 2019, Nature.
[7] Alison Cave,et al. Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe , 2019, Clinical pharmacology and therapeutics.
[8] W. Mackillop,et al. Real-world data: towards achieving the achievable in cancer care , 2019, Nature Reviews Clinical Oncology.
[9] Hun-Sung Kim,et al. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records , 2018, Journal of Korean medical science.
[10] E. Perfetto,et al. PEER-REVIEWED JOURNAL EDITORS’ VIEWS ON REAL-WORLD EVIDENCE , 2018, International Journal of Technology Assessment in Health Care.
[11] A. Kent,et al. EU Health Policy, Coherence, Stakeholder Diversity and Their Impact on the EMA , 2017, Biomedicine Hub.
[12] D. Lacombe,et al. Diverging EU health regulations: The urgent need for co ordination and convergence , 2017, Journal of Cancer Policy.
[13] H. Hillege,et al. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[14] P. Franklin. Public health within the EU policy space: a qualitative study of Organized Civil Society (OCS) and the Health in All Policies (HiAP) approach. , 2016, Public health.
[15] Erik Schultes,et al. The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.
[16] E. D. Gregorio. The path forward. , 2015 .
[17] T. Sudhop,et al. A 1-year cross-sectional analysis of non-interventional post-marketing study protocols submitted to the German Federal Institute for Drugs and Medical Devices (BfArM) , 2013, European Journal of Clinical Pharmacology.
[18] 서정헌,et al. 반도체 공정 overview , 2001 .
[19] Captain Y. B. Nusfield,et al. Public Health , 1906, Canadian Medical Association journal.
[20] Charline Morichon. EUROPE'S BEATING CANCER PLAN , 2020 .
[21] EU guidelines on ethics in artificial intelligence : Context and implementation , 2019 .